LB090 - SPECIALIZED ORAL NUTRITIONAL SUPPLEMENTATION IMPROVES INTAKE IN PATIENTS WITH METASTATIC COLORECTAL CANCER UNDERGOING CHEMOTHERAPY: A RANDOMIZED CLINICAL TRIAL

Linked sessions

LB090

SPECIALIZED ORAL NUTRITIONAL SUPPLEMENTATION IMPROVES INTAKE IN PATIENTS WITH METASTATIC COLORECTAL CANCER UNDERGOING CHEMOTHERAPY: A RANDOMIZED CLINICAL TRIAL

D. C. Nogueira e Silva 1, A. D. D. L. B. Martins1, A. C. Zanini2, E. L. Razzera2, H. D. Santos2, A. P. T. Fayh3,*

1Postgraduate Program in Nutrition, Federal University of Rio Grande do Norte, Natal, 2Scientific Department, Prodiet Medical Nutrition, Curitiba, 3Postgraduate Program in Nutrition Sciences, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil

 

Rationale: Oral nutritional supplementation (ONS) is recommended to prevent malnutrition in patients with cancer undergoing chemotherapy. However, evidence supporting these benefits in metastatic colorectal cancer (mCRC) remains limited.

Methods: A randomized clinical trial involving patients with mCRC undergoing chemotherapy. Participants were randomly assigned to the intervention group (IG): nutritional counseling combined with a specialized high-protein ONS with L-leucine and zinc (Immax - Prodiet) for 60 days; or to the control group (CG): only nutritional counseling. ONS dosage was individualized. Longitudinal changes were assessed using linear mixed-effects models. Between-group differences from baseline to visit 4 were evaluated using independent-samples t-tests and confirmed using Mann-Whitney U tests.

Results: Fifty-two patients were included (30 in the IG). Protein intake trajectories differed significantly between groups during follow-up (group x time interaction, p = 0.018). Baseline protein intake was similar between groups (1.60 vs. 1.25 g/kg, p = 0.243) but increased in the IG over time (+0.43 g/kg) and decreased in the CG (-0.29 g/kg), resulting in a between-group difference of 0.73 g/kg (95% CI 0.24 to 1.21; p = 0.004). Energy intake showed a similar trend, decreasing by 4.9 kcal/kg in the CG and increased by 6.5 kcal/kg in the IG, with a between-group difference of 11.4 kcal/kg (95% CI 0.7 to 22.1; p = 0.037). Although the overall group-by-time interaction did not reach statistical significance (p = 0.090), a significant difference between groups was observed at final visit (p = 0.012).

Conclusion: In patients with mCRC undergoing chemotherapy, nutritional counseling combined with a specialized ONS improved protein and energy intake compared with nutritional counseling alone, supporting its use to optimize nutritional management.

Disclosure of Interest: D. Nogueira e Silva : None declared, A. Martins: None declared, A. Zanini Other: Prodiet Medical Nutrition Employee, E. Razzera Other: Prodiet Medical Nutrition Employee, H. Santos Other: Prodiet Medical Nutrition Employee, A. P. T. Fayh: None declared